MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2018 International Congress

    Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

    M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

    Objective: Here we explore the efficacy of an oral treatment with Fingolimod (FTY720), a selective sphingosine-1-phosphate receptors modulator, to prevent MPTP induced nigrostriatal loss and…
  • 2018 International Congress

    The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America

    W. Oertel, H. Müller, C. Schade-Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, M. Unger, K. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

    Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…
  • 2018 International Congress

    What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

    T. Dominey, S. Buff, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

    Objective: To evaluate variation in Phase 2 and 3 Parkinson’s disease (PD) neuroprotective trial designs and identify key trial design features in Phase 2 studies…
  • 2018 International Congress

    A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease

    H. Huttunen, S. Booms, J. Koskinen, M. Saarma (Espoo, Finland)

    Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…
  • 2018 International Congress

    The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease

    P. Dharmasaroja, P. Chanthammachat (Bangkok, Thailand)

    Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…
  • 2018 International Congress

    Rose Anthocyanins protect against Parkinson’s pathophysiology: Behavioral and biochemical changes in young Drosophila

    G. Chandran, P. Chandrashekar, M. Jayaraju, J. Chauhan (Mysuru, India)

    Objective: To test the hypothesis that Rose Anthocyanins, owing to their biological properties in vitro, protect against Parkinson’s pathophysiology in young Drosophila melanogaster. Background: Anthocyanins…
  • 2018 International Congress

    An investigation of the potential neuroprotective role of curcumin in Parkinson’s disease patient-derived fibroblasts

    S. Abrahams, C. vander Merwe, A. Neethling, J. Carr, S. Bardien (Cape Town, South Africa)

    Objective: To investigate if the protective effects of curcumin previously observed in SH-SY5Y cells are also found in patient-derived fibroblasts from Parkinson’s disease patients. Background:…
  • 2018 International Congress

    Cognitive Reserve and Physical Activity Modulate Functional Brain Re-organisation in Premanifest Huntington’s Disease: Preliminary Evidence

    M. Soloveva, S. Jamadar, G. Poudel, N. Georgiou-Karistianis (Melbourne, Australia)

    Objective: In this study, for the first time we examined the relationship between cognitive reserve, sleep quality and current level of physical exercise and functional…
  • 2018 International Congress

    MANF improves the MPP+/MPTP-induced Parkinson’s disease via improvement of mitochondrial function and inhibition of oxidative stress

    Y. Liu, J. zhang, Q. Cai, H. Sun, L. Jin (Shanghai, China)

    Objective: This study aimed to investigate the therapeutic effect of mesencephalic astrocyte-derived neurotrophic factor (MANF) on the MPTP/MPP+-induced model of Parkinson's disease (PD) and the…
  • 2018 International Congress

    Cognitive effects of SIRT6 overexpression: Emerging role of astrocytes

    N. Lev, Y. Barhum (Kfar Saba, Israel)

    Objective: The aim of this work was to elucidate the effect of SIRT6 overexpression on cognition. Background: Recent evidence show that astrocytes are important for higher brain…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley